Health Shorts

April 2002

April is Cancer Control Month

American Cancer Society Cancer Detection Guidelines

Cancer-Related Checkup
A cancer-related checkup is recommended every 3 years for people aged 20-40 and every year for people age 40 and older. This exam should include health counseling and depending on a person's age might include examinations for cancers of the thyroid, oral cavity, skin, lymph nodes, testes, and ovaries as well as for some non-malignant diseases.

Special tests for certain cancer sites are recommended as outlined below.

Breast

  • Breast self-exam monthly for women aged 20 and over
  • Breast clinical physical examination for women aged 20 - 40, every 3 years; over 40, every year. This exam should be done close to the time of the scheduled mammogram. Ideally, the clinical breast exam should be done before the scheduled mammogram.
  • Mammography for women aged 40 and over, every year.

Colon and Rectum
Beginning at age 50, both men and women should follow one of these five testing schedules:

  • Yearly fecal occult blood test (FOBT)*
  • Flexible sigmoidoscopy every 5 years**
  • Yearly fecal occult blood test plus flexible sigmoidoscopy every 5 years*,**
  • Double-contrast barium enema every 5 years
  • Colonoscopy every 10 years**

**The combination of FOBT and flexible sigmoidoscopy is preferred over either of these two tests alone.

*For FOBT, the take-home multiple sample method should be used.

All positive tests should be followed up with colonoscopy.

People should begin colorectal cancer screening earlier and/or undergo screening more often if they have any of the following colorectal cancer risk factors.

  • a personal history of colorectal cancer or adenomatous polyps
  • a strong family history of colorectal cancer or polyps (cancer or polyps in a first-degree relative younger than 60 or in two first-degree relatives of any age) Note: a first degree relative is defined as a parent, sibling, or child.
  • a personal history of chronic inflammatory bowel disease
  • families with hereditary colorectal cancer syndromes (familial adenomatous polyposis and hereditary non-polyposis colon cancer).

Cervical

  • Pap test and pelvic examination for women who are or have been sexually active or have reached age 18, every year; after 3 or more consecutive satisfactory normal annual exams, the Pap test may be performed less frequently at the discretion of the physician.

Endometrium

  • The American Cancer Society recommends that all women should be informed about the risks and symptoms of endometrial cancer, and strongly encouraged to report any unexpected bleeding or spotting to their doctors. For women with or at high risk for hereditary nonpolyposis colon cancer (HNPCC), annual screening should be offered for endometrial cancer with endometrial biopsy beginning at age 35.

Prostate
Guideline Statement: Both Prostate-Specific Antigen (PSA) and Digital Rectal Examination (DRE) should be offered annually, beginning at age 50 years, to men who have at least a 10-year life expectancy. Men at high risk should begin testing at age 45 years. Information should be provided to men regarding potential risks and benefits of early detection and treatment of prostate cancer.

  • Men who choose to undergo testing should begin at age 50 years. However, men in high risk groups, such as African Americans and men who have a first-degree relative diagnosed with prostate cancer at a young age, should begin testing at 45 years. Note: a first-degree relative is defined as a father, brother, or son.
  • Men who ask their doctor to make the decision on their behalf should be tested. Discouraging testing is not appropriate. Also not offering testing is not appropriate.
  • Testing for prostate cancer in asymptomatic men can detect tumors at a more favorable stage (anatomic extent of disease). There has been a reduction in mortality from prostate cancer, but it has not been established that this is a direct result of screening.
  • An abnormal Prostate-Specific Antigen (PSA) test result has been defined as a value of above 4.0 ng/ml. Some elevations in PSA may be due to benign conditions of the prostate.
  • The Digital Rectal Examination (DRE) of the prostate should be performed by health care workers skilled in recognizing subtle prostate abnormalities, including those of symmetry and consistency, as well as the more classic findings of marked induration or nodules. DRE is less effective in detecting prostate carcinoma compared with PSA.

References
The above information is from the American Cancer Society - www.cancer.org.

American Cancer Society. Cancer Facts and Figures, 2002. Atlanta, GA: American Cancer Society;, 2002

Archive

August 2008
July 2008
June 2008
May 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
April 2007
April 2007
March 2007
February 2007
January 2007
December 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
Decmber 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
December 2003
November 2003
October 2003
September 2003
August 2003
July 2003
June 2003
May 2003
April 2003
March 2003
February 2003
January 2003
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
April 2002
November 2006


The information on this site is intended to increase your awareness and understanding of specific health issues. It should not be used for diagnosis or as a substitute for health care by your physician.